Trellis Bioscience Secures $9 Million for Calpurbatug Development
Funding will advance clinical trials for a novel treatment for infections.
Trellis Bioscience has successfully raised $9 million in Series C financing to further the clinical development of Calpurbatug (TRL1068), an innovative monoclonal antibody therapy aimed at treating chronic prosthetic joint infections (PJI). This funding is crucial for completing the company's ongoing Phase 2 clinical trial, which is currently fully enrolled.
The latest financing round saw participation from existing investors like New Science Ventures and Easton Capital, alongside new contributors including the AMR Action Fund and The Doctor Group, as well as orthopedic surgeons specializing in PJI. This brings Trellis's total funding to around $35 million, bolstered by similar amounts in non-dilutive grants from the National Institute of Allergy and Infectious Diseases (NIAID) and CARB-X.
Calpurbatug is designed to combat antibiotic-resistant infections by disrupting bacterial biofilm, which is a significant barrier to effective treatment. The standard management of PJI typically involves invasive surgical procedures that can severely impact patient quality of life, with costs potentially exceeding $400,000 per patient.
Geoff Dillon, CEO of Trellis, highlighted the importance of this funding, stating, "We're excited to have the backing of AMRAF, the most prominent investor in the antimicrobial space, as we move ahead in our efforts to redefine how antibiotic-resistant infections are treated in the future." The current treatment landscape for PJIs is limited, making this research particularly relevant as the incidence of such infections is projected to grow with the aging U.S. population.
The Phase 2 trial for TRL1068 aims to provide further clinical evidence of its efficacy in enhancing the DAIR procedure, which is a less invasive alternative to the traditional two-stage surgical revision. Early results from the ongoing trial are expected to be released in the second quarter of 2027.
Trellis has received multiple designations from the FDA, including Orphan Drug and Fast Track status, which could help the development process and regulatory review. The company's approach aims not only to improve patient outcomes but also to address the broader challenge of antimicrobial resistance.
This announcement was made public through PR Newswire.
This is an independent summary of a press release originally distributed via PR Newswire. GAX Online was not paid for this coverage.
Have news to announce?
Get your launch, funding round, or partnership covered on GAX Online, in front of tech buyers and the AI answer engines that cite us.
Submit your press release →